Get in touch

Dymista^®^ “can be considered the drug of choice”^1^ |For moderate/severe allergic rhinitis in patients 12 and over|


Adverse events should be reported.

Reporting forms and information can be found at

Adverse events should also be reported to

1. Leung et al. MP29-02: A major advancement in the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129(5): 1216.